Alternative analysis of mpox vaccine effectiveness data from Israel

Marc Lipsitch, DPhil* and Christopher B. Boyer, PhD
Center for Communicable Disease Dynamics, Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA 02115 USA

*corresponding author mlipsitc@hsph.harvard.edu

Text including introductory/abstract paragraph: 934 words
1 figure
1 table

Code available at https://github.com/c2-d2/NM-mpox-reanalysis

This work was supported by the Morris-Singer Fund's gift to the Center for Communicable Disease Dynamics.

Data availability statement: all data obtained from the published paper on which this comments.

Wolff Sagy et al.[1] report that a single dose of MVA-BN mpox vaccine was 86% effective in preventing incidence of diagnosed mpox. In their cohort study, all eligible men were enrolled on July 31, 2022 and followed until they tested positive for mpox or December 25, 2022, whichever was earlier. Individuals vaccinated after July 31 were considered unvaccinated from Day 0 through their date of vaccination; they were considered vaccinated from their date of vaccination, which was set as Day 0 for their follow up as a vaccinated person. Incidence was compared using Cox regression on this time scale, with typically different calendar days being Day 0 for vaccinated and unvaccinated persons. The study estimates a vaccine effectiveness of 86%. In this communication we estimate the magnitude of confounding by calendar time in the analysis[1] and argue that the true vaccine effectiveness was likely considerably lower than estimated during the study period.

The authors note: "Another possible source of bias is the variation of exposure to mpox during the study period."[1] This bias can arise if, as in the study, incidence decreases with time, because vaccinated person-time will be later than unvaccinated person-time, so vaccinated persons will experience lower incidence irrespective of any vaccine effect. This bias is a form of confounding by calendar time that can readily arise in infectious diseases where incidence can vary dramatically in time. The authors note that a test of Schoenfeld residuals fails to reject the null hypothesis of proportional hazards and conclude that this suggests confounding was not substantial. Importantly, this test is not designed to assess confounding and has limited power, especially in a data set with just 21 outcomes.

METHODS AND RESULTS

Given that the failure to reject proportional hazards is not strong evidence that the analysis is unconfounded by time, we sought to estimate the magnitude of this potential bias. To do so, we first estimated the number vaccinated each week as the difference between the number of vaccinated persons reported at risk in Figure 1 of ref. 1 in successive weeks of follow-up, starting from the end. For example, 76 persons vaccinated in week 1; 504 – 76 = 428 in week 2; 617-504 = 113 in week 3, and so forth. This estimation works because the number followed for the whole period should be the number vaccinated by week 1; the number followed for all but one week would be the number vaccinated by week 2; and so forth. The use of weeks rather than days may introduce some error to this estimate. Most incidence in the control group happened at a near constant rate over the first 4 weeks (13 of 16 cases) (Ref 1, Fig. 1), yet 34% [(1037-689)/1037] of the vaccinated group did not experience this high-incidence period while vaccinated, strongly violating the principle that in causal inference, the experience of the unexposed should reflect what would have happened to the exposed group, had they (counterfactually) been unexposed. This calculation suggests that confounding by calendar time, which breaks that equivalence, could induce substantial bias in this study.

Using this estimate of the timing of vaccinations, in Table 1 we estimated the number of cases that would have occurred in the vaccinated group if the vaccine had been 0% effective; that is, we calculated for each week of follow up the product of the number of persons vaccinated by that week and the incidence rate in the unvaccinated group, and summed this product over all weeks. For the number in the unvaccinated group each week, we used the number unvaccinated at risk in the first week in Figure 1 of Ref. 1 (1017), plus the number of individuals eventually vaccinated (1037), minus the number whom we estimated above had been vaccinated by that calendar week.

This method estimates 7.5 expected cases in the vaccinated group under the null hypothesis of no vaccine effect (Fig. 1 of this communication). A crude estimate of vaccine effectiveness would compare the observed number of infections in the vaccinated group to the number expected if the vaccine had had no effect: this would be 100%-5/7.5 = 33%, compared to a crude estimate from the study data of 1-5/16=69%. While it is impossible from the summary data published to estimate the fully adjusted vaccine effectiveness, the fact that approximately accounting for the lower incidence during the vaccinated person-time reduces the crude effectiveness estimate by more than half suggests the bias could be large and suggests that the true effectiveness in this study was likely substantially lower than the adjusted effectiveness of 86% that was reported.

R code for generating these estimates is included as supplementary material.

DISCUSSION

In principle, an observational study of vaccine effectiveness that is designed to emulate a emulate a target randomized trial can prevent not only this form of time-dependent confounding, but also immortal time bias[2], avoidance of which was stated by the authors to motivate their analytic approach. While many such trials could be specified, one approach that has been used is, on the day of vaccination for each vaccinated person, to match them with an unvaccinated person and follow them over the same portion of calendar time, until either has the outcome, the unvaccinated one is vaccinated, or the end of followup. In this case, that approach might have had limited power because most cases in the unvaccinated occurred during the first three calendar weeks of the study period, and as noted above vaccination was just beginning to occur during this high-incidence time. Nevertheless, an underpowered approach is preferable to one that may lead to dramatic upward bias in effectiveness estimates.

REFERENCES

1. Wolff Sagy, Y.*, et al.* Real-world effectiveness of a single dose of mpox vaccine in males. *Nat Med*, 1-5 (2023).
2. Hernan, M.A., Sauer, B.C., Hernandez-Diaz, S., Platt, R. & Shrier, I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. *J Clin Epidemiol* **79**, 70-75 (2016).

AUTHOR CONTRIBUTIONS

ML and CBB conceived the manuscript and performed the analyses. ML wrote the first draft and both authors revised it for important scientific content.

Table 1: Calculation of the number of cases among vaccinated that would have occurred if they experienced the same incidence rate as unvaccinated (i.e. VE = 0%)

Date	Unvaccinated (N)	Cumulative Cases (N)	Weekly Incidence rate (N per 1000)	Vaccinated (N)	Vaccinated x Incidence rate
Jul 31	1,978	0	0.0	76	0.0
Aug 07	1,546	4	2.6	504	1.3
Aug 14	1,427	10	4.2	617	2.6
Aug 21	1,352	13	2.2	689	1.5
Aug 28	1,301	14	0.8	739	0.6
Sep 04	1,252	15	0.8	787	0.6
Sep 11	1,209	15	0.0	830	0.0
Sep 18	1,164	15	0.0	875	0.0
Sep 25	1,107	16	0.9	932	0.8
Oct 02	1,042	16	0.0	996	0.0
Oct 09	1,025	16	0.0	1,013	0.0
Oct 16	1,020	16	0.0	1,018	0.0
Oct 23	1,014	16	0.0	1,024	0.0
Oct 30	1,012	16	0.0	1,026	0.0
Nov 06	1,009	16	0.0	1,029	0.0
Nov 13	1,005	16	0.0	1,033	0.0
Nov 20	1,004	16	0.0	1,034	0.0
Nov 27	1,004	16	0.0	1,034	0.0
Dec 04	1,004	16	0.0	1,034	0.0
Dec 11	1,001	16	0.0	1,037	0.0
Dec 18	1,001	16	0.0	1,037	0.0

Date	Unvaccinated (N)	Cumulative Cases (N)	Weekly Incidence rate (N per 1000)	Vaccinated (N)	Vaccinated x Incidence rate
Dec 25	1,001	16	0.0	1,037	0.0
TOTAL					**7.5**



Figure 1: Cumulative mpox cases over follow up comparing vaccinated to unvaccinated and vaccinated if they had experienced the same incidence rate as unvaccinated.